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ABSTRACT
Multiple myeloma (MM) is a fatal and incurable hematological malignancy thus 
new therapy need to be developed. Cold atmospheric plasma, a new technology 
that could generate various active species, could efficiently induce various tumor 
cells apoptosis. More details about the interaction of plasma and tumor cells need 
to be addressed before the application of gas plasma in clinical cancer treatment. 
In this study, we demonstrate that He+O2 plasma could efficiently induce myeloma 
cell apoptosis through the activation of CD95 and downstream caspase cascades. 
Extracellular and intracellular reactive oxygen species (ROS) accumulation is essential 
for CD95-mediated cell apoptosis in response to plasma treatment. Furthermore, p53 
is shown to be a key transcription factor in activating CD95 and caspase cascades. 
More importantly, we demonstrate that CD95 expression is higher in tumor cells 
than in normal cells in both MM cell lines and MM clinical samples, which suggests 
that CD95 could be a favorable target for plasma treatment as it could selectively 
inactivate myeloma tumor cells. Our results illustrate the molecular details of plasma 
induced myeloma cell apoptosis and it shows that gas plasma could be a potential 
tool for myeloma therapy in the future.
INTRODUCTION
Multiple myeloma (MM), the second most 
common hematological malignancy characterized by the 
accumulation of malignant plasma cells (PCs) in the bone 
marrow (BM) of patients, results in the production of 
monoclonal immunoglobulin (also known as ‘M-protein’) 
and substantial immune-suppression and end-organ 
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damage such as anemia, thrombocytopenia, renal failure, 
and bone disease [1]. In nonrandomized MM clinical 
trials, high-dose chemotherapy is recommended with 
an autologous transplant, which results in the highest 
response rates [2, 3]. However, despite great progress 
in novel anti-myeloma drugs and therapies, most of the 
patients relapse and become resistant to chemotherapy 
[4], which makes MM a fatal and incurable hematological 
malignancy. Regulation of redox homeostasis is one 
strategy for cancer treatment, as long-term ROS 
simulation plays an important role in cancer development 
through oxidative DNA damage and gene mutations [5, 
6]. Radiation and several chemotherapy drugs can produce 
extracellular and intracellular ROS, thus disrupting redox 
homeostasis, which can induce tumor cell apoptosis [7, 8]. 
Cell apoptosis are mainly conducted by three pathways: 
mitochondrial pathway, extrinsic pathway such as death 
receptors (DR) and tumor necrosis factor receptor (TNF), 
endoplasmic reticulum (ER) stress pathway [9, 10]. In this 
study, we investigated whether CD95, a key death receptor 
that is pivotal for the induction of tumor cell apoptosis and 
is a major target in cancer therapy [11, 12], is involved 
in plasma induced cell apoptosis. It was reported that 
CD95 is widely expressed in patient myeloma cells 
and myeloma cell lines [13, 14]. Anti-CD95 antibodies 
could directly target CD95; however, only some samples 
exhibited cell apoptosis [15]. ROS accumulation could 
also regulate CD95, thus activating CD95-mediated 
tumor cell apoptosis [16, 17]. In addition to radio- and 
chemotherapies, a new technology called cold atmospheric 
plasma (CAP) could provide controllable exogenous 
reactive oxygen and nitrogen species [18, 19]. Plasmas are 
ionized gases, comprising a complex mixture of charged 
particles, neutral gas molecules, UV radiation, electric 
fields and reactive species [20]. Owing to technological 
advancements, it is now possible to generate plasmas at 
atmospheric pressure and room temperature (e.g., CAP), 
which enables the application of plasma in a range of 
biomedical processes such as wound healing, disinfection 
and cancer treatment [21, 22]. Most plasma devices could 
be divided into two types: plasma jet and Dielectric 
Barrier Discharger (DBD) [23–25]. CAP is a favorable 
source of reactive oxygen and nitrogen species, and it has 
been found to be efficient for killing tumor cells in various 
types of cancer, including lung cancer, leukemia, intestinal 
cancer, melanoma, cervical cancer, glioma, pancreatic 
cancer et al. [26–29]. The induction of apoptosis in cancer 
cells has been widely reported, and the mechanism of 
plasma-induced apoptosis is increasingly being understood 
[30–32]. It is reported that plasma could affect various 
cancer cell signaling such as AGP-ROS, MAPK, p53 and 
PI3K/AKT pathway and induced cell apoptosis [33]. In 
this study, we first demonstrated that CD95 was involved 
in plasma-induced cancer cell apoptosis. Up-regulation 
of CD95 was positively correlated with the accumulation 
of extracellular and intracellular ROS. By chromatin 
immune-precipitation (ChIP) assay, we demonstrated that 
p53, which was up-regulated by plasma treatment, could 
bind to the CD95 promoter region and increase CD95 
expression, resulting in the activation of caspase signaling 
and induction of apoptosis. Furthermore, because of the 
differential expression of CD95 in normal and myeloma 
cells, plasma could selectively inactivate tumor cells 
in myeloma cell lines and patient samples. Our results 
provide a new strategy for potential myeloma therapy by 
targeting CD95 with cold atmospheric plasma.
RESULTS
Characteristics of plasma generation
He plasma was generated at the voltage of 10 kHz/8 
kV with a He gas flow of 2 SLM. Additional O2 was mixed 
in to produce more ROS. (Figure 1A and 1B) show the 
structure of the plasma jet and photographs of He/He+O2 
plasmas. Additional O2 decreased the intensity of the plasma 
and changed the plasma plume from purple to gray. (Figure 
1C) shows the corresponding applied voltage and current 
during He+O2 plasma generation. To investigate the different 
reactive species in the plasma, we used a spectrometer to 
measure the emission spectra. As shown in (Figure 1D), there 
were several spectral lines (e.g., OH (A) 309 nm, N2 (C) 337 
nm, N2
+ (B) 391 nm, He (3s3S1) 706 nm and O (3p5P) 777 
nm) present in the plasma and they were marked according to 
the literature [34, 35]. The intensity of the plasma components 
gradually decreased when the percentage of mixed O2 was 
increased from 0% to 1% (Figure 1E).
Decrease in cell viability and induction of 
apoptosis after plasma treatment for different 
durations
We treated LP-1 MM cells with CAP and 
investigated the biological effects of plasma. CellTiter-
Glo assay showed that the cell viability 24 h and 48 h 
after He plasma treatment gradually decreased in a time-
dependent manner (Figure 2A). Next, we added O2 to 
He to generate He+O2 plasma, which could produce 
more ROS. We added O2 at 0.2%, 0.5% and 1% of the 
total mixture. Because O2 is a electronegative gas, a 
mixture with greater than 1% of O2 will eliminate plasma 
generation. (Figure 2B) shows the cell viability 24 h after 
the application of the various compositions of He+O2 
plasma. The addition of 0.2% O2 didn’t promote LP-1 
cell death compared to He+0% O2, and the cell viability 
of He+0.5% O2 treatment was sharply decreased and 
much lower than other groups when the treatment time 
was over 30 s. Referring to the intensity and stability 
of the plasma (Figure 1E), we chose the He+0.5% O2 
plasma for use in our following experiments. (Figure 2C) 
shows apoptosis in the cells detected by flow cytometry 
24 h after He+0.5% O2 treatment.
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Figure 1: Characteristics of the plasma generation system. (A) Schematic representation of the plasma jet. (B) Photographs of 
He plasma and He+O2 plasmas. (C) Monitoring of the applied voltage and current during He+O2 plasma generation. (D) Emission spectra 
of different He+O2 plasmas detected by the spectrometer. Some unique spectral lines (OH, N2, He and O) in the He+0.5% O2 plasmas are 
marked. (E) The intensity of several characteristic spectral lines are shown with varying O2 percentage in the working gas.
Figure 2: Cell viability and apoptosis after plasma treatment for different durations. (A) Analysis of cell viability 24 h 
and 48 h after He plasma treatment for different durations. (B) Analysis of cell viability 24 h after He+O2 plasma for different 
durations. (C) Cell apoptosis analyzed by flow cytometry after He+0.5%O2 plasma treatment for 0.5, 1, and 2 min.
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Changes in mitochondrial membrane potential 
(MMP), lysosomal leakage and activation of the 
caspase cascades after plasma treatment
Changes in MMP (JC-1 staining) are known 
indicators of early apoptosis [11]. By fluorescence 
microscopy, we showed that the red fluorescence (JC-1 
aggregates) declined after He+O2 plasma treatment (Figure 
3A), which was further confirmed by flow cytometry 
(Figure 3B). Lysosomal leakage assay (stained by lucifer 
yellow dye) showed that plasma treatment resulted in the 
release of the dye from lysosomes into the cytoplasm, 
generating diffuse green staining instead of the punctate 
pattern seen in the control (Figure 3C). Since the activation 
of caspase cascades plays a central role in apoptosis, we 
investigated enzyme activity of caspase3/8/9 at 3 h and 
6 h after He+O2 plasma treatment. The results showed 
that the enzyme activity of caspase3/8 was increased 
by plasma treatment, while that of caspase9 increased 
slightly only at 6 h after treatment (Figure 3D). Western 
blotting results showed that caspase3/8/9 (32 kD, 31 kD 
and 18 kD, respectively) were all increased after plasma 
treatment (Supplementary Figure 1). Cleaved caspase8 
(43 kD and 41 kD) exhibited a significant increase, 
while that of caspase8 (55 kD) remained the same after 
plasma treatment. The level of caspase9 (47 kD) was 
slightly increased after plasma treatment. These results 
indicated that caspase3 and caspase8 were the main factors 
activating the apoptotic process.
Analysis of apoptosis-related protein array after 
He+O2 plasma treatment
To elucidate the molecular mechanism of plasma-
induced cell apoptosis, a human apoptosis protein array 
containing 35 apoptosis-related proteins was used 24 
h after He+O2 treatment for 60 s. As shown in (Figure 
4A), the level of cytochrome C was decreased, while 
that of CD95 and phospho-p53 was significantly 
increased by plasma treatment. As CD95 is a key cell 
Figure 3: MMP, lysosomal leakage and caspase activation induced by plasma treatment. (A, B) LP-1 cells stained with 
a reporter dye, JC-1, for mitochondrial condition are detected by (A) fluorescence microscopy and (B) flow cytometry. (C) Analysis of 
lysosomal leakage in LP-1 cells indicated by fluorescence staining with Lucifer yellow after plasma treatment for 0.5, 1 and 2 min. (D) The 
activity of caspase3/8/9 was measured with a Caspase Colorimetric Assay Kit 3 h and 6 h after plasma treatment.
Oncotarget18006www.oncotarget.com
death receptor (DR), we confirmed CD95 expression 
by flow cytometry after plasma treatment. The results 
showed that CD95 was up-regulated in a time-
dependent manner by He+O2 treatment (Figure 4B). 
These results indicated that CD95 might be involved in 
plasma-induced cell apoptosis.
Down-regulation of CD95 reduced plasma-
induced cell apoptosis
We used CD95-targeting short interfering RNAs 
(siRNA) to down-regulate CD95 expression and assessed 
the effect of plasma on cell apoptosis. 48 h after siRNA 
transfection, we detected CD95 expression by flow 
cytometry, real-time PCR and western blotting. As 
shown in (Figure 5A), the percentage of CD95+ cells was 
decreased after siRNA transfection. CD95 expression at 
mRNA and protein levels was also decreased compared 
to that of the control. The percentage of CD95+ cells 
(Figure 5B) and corresponding cell viability (Figure 
5C) after CD95 knockdown and plasma treatment 
was investigated. CD95 expression and cell viability 
was negatively correlated. Down-regulating CD95 
could reduce cell viability reduction caused by plasma 
treatment. By Annexin-V/PI staining, we further 
confirmed that compared to the control, down-regulation 
of CD95 could reduce cell apoptosis induced by He+O2 
plasma treatment for 1 min (Figure 5D). These results 
indicated that CD95 is involved in He+O2 plasma-
induced cell apoptosis.
ROS accumulation is essential for CD95-
mediated cell apoptosis by plasma treatment
As ROS produced by plasma are considered to play 
an important role in biological processes, we investigated 
extracellular and intracellular levels of ROS after He+O2 
plasma treatment. Extracellular ROS level was significantly 
increased immediately after plasma treatment, while at 
24 h and 48 h after treatment, it was only slightly higher 
than the level before treatment (Figure 6A). NAC, which 
is a general ROS scavenger, could efficiently eliminate 
extracellular ROS accumulation at a final concentration of 
5 mM or 10 mM. Meanwhile, NAC alone (5 mM or 10 
mM) had no cell toxicity on LP-1 cells as no reduction of 
cell viability was detected after adding NAC for 24 h and 48 
h. Intracellular ROS was detected by flow cytometry, and 
the results showed that there was no difference immediately 
after plasma treatment, or in a short time (3 h and 6 h) 
after plasma treatment (data not shown), but the level was 
significantly increased 24 h after plasma treatment (Figure 
6B). NAC not only eliminated extracellular ROS but also 
blocked the intracellular ROS accumulation despite the 
various durations of plasma treatment. Cell viability assay 
revealed that preventing ROS accumulation by NAC could 
reduce plasma-induced cell apoptosis measured at 0 h, 
24 h and 48 h (Figure 6C). Furthermore, elimination of 
extracellular and intracellular ROS accumulation by NAC 
prevented the increase in the expression of CD95 by plasma 
treatment measured by flow cytometry, real-time PCR and 
western blotting (Figure 6D).
Figure 4: Analysis of apoptosis-related protein array and CD95 expression after plasma treatment. (A) Cell apoptotic 
apoptosis-related protein array detection was performed 24 h after He+O2 plasma treatment for 1 min. (B) CD95 expression was measured 
by flow cytometry 24 h after He+O2 plasma treatment for 0.5 min, 1 min and 2 min. IgG was used as the isotype control of CD95. 
Percentage of CD95 expression and MFI ratio were expressed in M±SD. * indicates p<0.05, ** indicates p<0.01
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p53 mediated CD95 up-regulation in plasma-
induced apoptosis
Using the apoptosis-related protein array we also 
detected an increase in phospho-p53 level after He+O2 
plasma treatment. In addition, several studies had 
reported that p53 was activated in response to plasma 
treatment and promoted cancer cell apoptosis [36–39]. We 
wondered whether p53 could regulate CD95 expression 
thus activating the downstream caspase pathway. PFT-α, 
a p53 inhibitor, was used in this study and could reduce 
cell apoptosis by plasma treatment (Figure 7A). Western 
Figure 5: Down-regulation of CD95 expression by siRNA reduced plasma-induced cell apoptosis. (A) CD95 expression 
detected by flow cytometry, real-time PCR and western blotting after siRNA-mediated knockdown for 48 h. IgG is the isotype control. Con 
indicates transfection of control scramble siRNA compared to CD95-targeting siRNA. (B, C) CD95 expression (B) and corresponding cell 
viability (C) 24 h after plasma treatment for 0.5 min, 1 min and 2 min. Con- and Con+ groups were transfected with control scramble siRNA 
and treated without or with He+O2 plasma. The siRNA
+ group represents cells treated with He+O2 plasma after knockdown of CD95 by 
siRNA. (D) Cell apoptosis was detected 24 h after He+O2 plasma treatment for 1 min following transfection. 
* indicates p<0.05.
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blotting showed that NAC and PFT-α could both decrease 
the expression of phospho-p53. Meanwhile, inhibition 
of p53 prevented the up-regulation of CD95 expression 
and the activation of caspase 3/8/9 detected by western 
blotting (Figure 7B). Since p53 is a transcription factor, 
using ChIP assay, we investigated whether p53 could 
bind to the promoter region of CD95 to regulate CD95 
expression. Indeed, our ChIP results demonstrated that 
phospho-p53 could bind to the promoter region of CD95 
mRNA and regulate mRNA expression, as a clear band 
was detected by electrophoresis in the sample treated 
with He+O2 plasma (Figure 7C). He+O2 plasma increased 
the binding of p53 to the CD95 promoter region (-1454 
upstream of the CD95 transcription initiation site) 
compared to the control and activated CD95 mRNA 
expression (Figure 7C). The details of sequence analysis 
are list in Supplementary Files (sequences analysis.doc).
Differential expression of CD95 and sensitivity of 
normal and myeloma cells to plasma treatment 
in cell lines and clinical samples
Since we demonstrated that CD95 is an important 
target in plasma-induced cell apoptosis, we wondered 
whether normal and tumor cells express different levels 
of CD95 and if the cells have differential sensitivity 
to plasma treatment. As shown in (Figure 8A), LP-1 
myeloma cells have a higher expression of CD95 
compared to normal cells (marrow stromal cells, MSC) 
detected by flow cytometry, real-time PCR and western 
blotting. Meanwhile, viability assay revealed that MM 
tumor cells were more sensitive to plasma treatment 
that MSC normal cells (Figure 8B). Similar to the data 
from MM cell lines, the tumor cells derived from MM 
patients displayed higher CD95 expression compared to 
Figure 6: Extracellular and intracellular ROS, cell viability and CD95 expression were measured after He+O2 plasma 
treatment with ROS scavenger (NAC). (A) Extracellular ROS level detected with a microplate reader at 0 h, 24 h and 48 h after 
plasma treatment for 0.5, 1 and 2 min with or without NAC. (B) Intracellular ROS level detected with a flow cytometer 24 h after plasma 
treatment without (above) or with (below) NAC. (C) Cell viability measured by CellTiter-Glo assay at 0 h, 24 h and 48 h after plasma 
treatment for 0.5, 1 and 2 min with or without NAC. (D) CD95 expression was detected by flow cytometry (left) and real-time PCR 
(middle) 24 h after He+O2 treatment and by western blot (right) 48 h after plasma treatment with or without NAC.
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normal control detected by flow cytometry (Figure 8C) 
and western blotting (Figure 8D). In addition, the tumor 
cells showed a significant reduction in cell viability 
after plasma treatment compared to the normal control 
(Figure 8E). By fluorescent in situ hybridization (FISH), 
we detected several common genetic alterations in MM 
that could predict the prognosis of MM patients. Patients 
with RB1 deletion and 13q14 deletion were considered 
to have moderate prognosis, while patients with 1q21 
amplification and 14q32 translocation were considered 
to have poor prognosis [35] (Supplementary Table 2). 
Interestingly, tumor cells derived from patients with poor 
prognosis were more sensitive to plasma treatment than 
those from patients with moderate prognosis (Figure 8F). 
Furthermore, we analyzed the viability differences of 
tumor cells and normal cells after plasma treatment and 
found that for the samples from patients with moderate 
prognosis, shorter plasma treatment (30 s) showed better 
selectivity, while that with poor prognosis, longer plasma 
treatment (60 s) showed better selectivity (Figure 8G). 
These data may provide useful treatment parameters for 
clinical therapy.
DISCUSSION
Plasmas are a mixture of charged particles, neutral 
gas molecules, UV radiation, and reactive species, among 
which, the reactive species were considered to be the 
most important factors for biological effects [40]. The 
temperature of plasma in our study is around 30°C, which 
has little heat effect on cells as cells were further cultured 
at 37°C in the incubator. This plasma jet generation 
system was used in our previous studies and characters 
of the plasma generation and electronic parameters were 
well illustrated in our previous works, including the 
distribution of various species by emission spectrum and 
mass spectrometer [28]. We also demonstrated that plasma 
jet could generate aqueous reactive species including OH, 
H2O2, O2
- and nitrite (HNO2/NO2
-), among which the long-
lived species (H2O2) could reach to μM concentration 
level [41, 42]. In this study, we found for the first time 
that CD95/FAS is a pivotal target that induces cancer cell 
apoptosis in response to plasma treatment. The activation 
of CD95 was positively correlated with the accumulation of 
extracellular and intracellular ROS. Interestingly, there was 
Figure 7: Involvement of p53 in CD95-mediated cell apoptosis by He+O2 plasma treatment. (A) Analysis of cell viability 
after plasma treatment for 0.5, 1 and 2 min with or without NAC or PFT-α (p53 inhibitor). (B) Western blot analysis of phospho-p53, 
caspase3/8/9 and CD95 expression after plasma treatment. NAC and PFT-α indicates that the ROS scavenger and p53 inhibitor were added 
respectively before plasma treatment for 2 min. (C) Interaction of p53 and CD95 promoter region in response to plasma treatment. The top 
panel shows the illustration of the CD95 promoter region and p53 binding site. The bottom panel shows the results of ChIP assay for p53 
and CD95 promoter detected by RT-PCR and real-time PCR. * indicates p<0.05.
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a time lag between the increase in extracellular ROS and 
the accumulation of intracellular ROS, as the former was 
significantly increased immediately after plasma treatment, 
but the latter could only be detected 24 h after plasma 
treatment. Only some small molecules such as H2O2 can 
catalytically permeate cells with the aid of the membrane 
transporters [43]. However, other ROS, such as OH radicals, 
cannot pass through the cell membrane owing to their high 
reactivity. Therefore, most of the intracellular ROS are 
generated inside the cells through signal transduction from 
the extracellular ROS. This can explain the time lag for the 
detection of intracellular ROS 24 h after plasma treatment. 
However, details regarding signaling transduction by ROS 
are mostly unknown because of the high reactivity and 
extreme short life of ROS.
We used He+O2 plasma in our study, as the addition 
of O2 can increase the production of ROS by plasma 
and cause more cell death. From the emission spectra, 
we confirmed that the He+O2 plasma generated more 
ROS such as OH, O777 and O845 compared to the He 
plasma. However, higher percentage of O2 in the He 
mixture can decrease plasma intensity or even inhibit 
plasma generation. Considering the plasma intensity and 
stability (monitored using electric current) along with its 
effects on cell viability, we chose the plasma generated 
from He+0.5% O2 for our subsequent experiments. 
Several studies also reported that He+O2 plasma could 
substantially reduce cancer cell viability [44, 45].
ROS production by other approaches (such as 
chemo-drugs) can also result in cell apoptosis through 
up-regulation of CD95, which has been reported in the 
literature [16, 46]. Here, we demonstrated that ROS 
production by plasma treatment, could lead to cell 
apoptosis via the activation of CD95 and downstream 
caspase cascade. By down-regulation of CD95, we 
confirmed that CD95 is a major executor in plasma-
Figure 8: Differential CD95 expression and sensitivity to plasma of cell lines and patient samples. (A) CD95 expression 
in MM tumor cells and normal cells (MSC) detected by flow cytometry, real-time PCR and western blotting. (B) Sensitivity of tumor and 
normal cells to plasma treatment assessed by cell viability assay. (C, D) CD95 expression detected by flow cytometry (C) and western 
blotting (D) in a representative patient sample. (E) Sensitivity of tumor and normal cells derived from patients assessed by cell viability 
assay 24 h after plasma treatment. (F) Sensitivity of MM tumor cells derived from patients with moderate and poor prognosis (analyzed 
by FISH) in response to plasma treatment, (G) Difference in viability of tumor and normal cells after plasma treatment in samples from 
patients with moderate and poor prognoses. * indicates p<0.05, ** indicates p<0.01.
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induced cell apoptosis. However, whether the extracellular 
ROS can directly affect CD95 to activate the caspase 
cascade remains unknown. By far, computer modeling 
could be a way to understand the interaction of small 
molecules (especially with high reactivity) with biological 
molecules [47]. In our study, we could only demonstrate 
with an ROS scavenger that ROS accumulation is 
necessary for CD95 activation by plasma. Interestingly, 
we also detected an increase in phospho-p53 in the protein 
array. The tumor suppressor protein p53 is a redox-active 
transcription factor that regulates various downstream 
targets and can induce cell apoptosis [48]. As a secondary 
messenger, ROS can activate p53 expression, thereby 
regulating downstream targets of p53 [49, 50]. Zalcenstein 
et al. reported that in H2O2-treated human cells, one-third 
of the highly responsive genes were targets of p53 [51]. 
Therefore, we investigated whether CD95 up-regulation 
in response to plasma treatment was mediated by p53. 
Using anti-phospho-p53 antibodies, we isolated the 
DNA fragments bound to p53. With well-designed PCR 
primers against the CD95 promoter region, we observed a 
significant increase in interaction between p53 and CD95 
promoter after He+O2 plasma treatment. Furthermore, p53 
inhibitor could reduce the up-regulation of CD95 induced 
by plasma treatment. Hence, for the first time, we reported 
the details of ROS/p53/CD95/caspase activation with a 
He+O2 plasma treatment system. By ChIP assay, Ruiz et 
al. reported the presence of p53-mediated up-regulation of 
CD95 gene expression upon genotoxic treatment in human 
breast tumor cells, which was consistent with our results 
showing that p53 could interact with CD95 promoter, 
thereby regulating its mRNA expression [52].
Unlike radiation, which can penetrate deep inside 
tissues, CAP has limited penetration. For topological 
treatment such as in dermatology and wound healing, 
direct plasma treatment could be applied. For other internal 
diseases, injection of plasma-activated medium (PAM) 
could be used. Many studies have reported the induction 
of cell death by PAM in various tumor cells such as 
glioblastoma cells, lung adenocarcinoma cells and ovarian 
cancer cells [53–56]. Understanding the mechanism of 
plasma-induced myeloma cell death will provide a better 
strategy for future clinical trials investigating the injection 
PAM into the blood or bone marrow. However, before gas 
plasma could be applied in clinical cancer treatment, the 
safety should also be concerned. It is revealed that plasma 
treatment could selectively induce tumor cells apoptosis 
but had little cytotoxicity on normal cells [53, 57]. Our 
previous study demonstrated that oral lavage of PAW 
treatment on immuno-deficient nude mice showed no 
significant safety problems without lethal effect and other 
acute toxicity [58]. Besides, some gas plasma devices 
have been applied in clinical trials, especially in wound 
healing [59, 60]. Some products in plasma medicine have 
been certified by the U.S. Food and Drug Administration 
(FDA) [61], although they all limited in skin treatment. In 
this study, we detected that the myeloma cells were more 
sensitive to plasma treatment compared to the normal 
stromal cells (MSC). Since we demonstrated that CD95 
is critical in plasma-induced apoptosis, we analyzed the 
differential expression of CD95 in cancer and normal 
cells. We found that CD95 expression was higher in 
tumor cells than in normal cells in both MM cell lines 
and clinical samples. Interestingly, we predicted prognosis 
by FISH to detect genetic alterations and found that 
cells from MM patients with poor prognosis were more 
sensitive to plasma treatment. This may partly be because 
patients with poor prognosis have a higher percentage 
of MM tumor cells in the bone marrow. These results 
further confirmed that CD95 could be a potential target 
for myeloma treatment with gas plasma.
In conclusion, we demonstrated that He+O2 plasma 
could efficiently induce cell apoptosis through the 
activation of CD95 and downstream caspase cascades. 
Extracellular and intracellular ROS accumulation was 
essential for CD95-mediated cell apoptosis in response 
to plasma treatment. Furthermore, p53 was shown to 
be a key transcription factor in activating CD95 and 
caspase cascades. Supplementary Figure 2 illustrates the 
schematic representation of He+O2 plasma-induced cell 
apoptosis mediated by ROS/p53/CD95/Caspase signaling. 
Meanwhile, we demonstrated that CD95 expression was 
higher in tumor cells than in normal cells in both MM cell 
lines and MM clinical samples, which suggests that CD95 
could be a favorable target for plasma treatment as it could 
selectively inactivate myeloma tumor cells.
MATERIALS AND METHODS
Plasma generation system
The cold atmospheric plasma used in this study was 
generated using a plasma jet described in our previous 
study [62]. And the schematic diagram of the device 
structure is shown in Figure 1A. A 1 mm stainless steel 
needle as a powered electrode enclosed in a length of 6 cm 
and inner and outer diameters of 4 mm and 6mm quartz 
tube respectively, which is 15 mm above the top of quartz 
tube. A length of 10mm copper sheet was wrapped around 
the quartz tube at a distance of 10 mm from the nozzle 
end serves as the ground electrode. The plasma generation 
system included a gas flow controller, high-voltage power 
supply, oscilloscope, and plasma jet. A gas flow of 2 SLM 
was used for He at 10 kHz/8 kV. Additional O2 was added 
in the gas flow to generate He+O2 plasma for more ROS 
production.
Cell culture conditions
The LP-1 multiple myeloma cells and MSC cells 
were used as control cells as described in our previous 
study [62]. These suspension cells were grown in 
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Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 10% fetal calf serum, 100 U/mL 
penicillin, and 50 μg/mL streptomycin (Corning, Ithaca, 
NY, USA). The cells were cultured at 37°C in an incubator 
(Thermo Scientific, Waltham, MA, USA) containing 5% 
CO2. The medium was refreshed 24 h before performing 
experiments, then 6 × 104 cells/ well in 100 μL medium 
were seeded on 96-well plate and 2 × 105 cells/ well 
in 300 μL medium were seeded on 24-well plate when 
performing the plasma treatment experiments.
Optical emission spectroscopy
Emission spectra of the plasma were measured using 
a UV/Visible spectrometer (Maya pro 2000, Ocean Optics, 
China) within a wavelength range of 200-800 nm. The 
emission spectra of He plasma with different percentage 
of O2 were analyzed in the vertical plane of the plasma jet. 
Because the intensity of light is highest at the point where 
the plasma touches air, the optical probe was mounted at 
the nozzle of the plasma jet generator, which guarantees a 
clear spectrum of particles in the plasma plume.
Cell viability assay
A Cell-Titer-Glo® luminescent cell viability assay 
kit (Promega, Madison, WI, USA) which based on the 
production of ATP in viable cells was used to measure 
cell viability. 100 μL of samples and 100 μL of Cell-Titer-
Glo® reagent were added to the opaque-walled multi-well 
plate, then the plate was incubated at room temperature 
for 10 min after mixing for 2 min on an orbital shaker. The 
luminescence was determined using the microplate reader 
((Thermo Scientific Varioskan Flash, Waltham, MA, USA) 
with the protocol of “luminometric” measurement.
Cell apoptosis assessment
We used Annexin V and PI (BioLegend, San 
Diego, CA, USA) double staining for the detection of cell 
apoptosis by flow cytometry. After treatment with plasma 
for 24 h, cells were washed twice with cell staining buffer 
and resuspended in 50 μL Annexin V binding buffer. 
Next, 2 μL Annexin V-APC and 2.5 μL PI were added 
and incubated for 15 min at room temperature in the 
dark. Then, 400 μL Annexin V binding buffer was added, 
followed by flow cytometry (Accuri C6; BD, USA).
Detection of MMP
Mitochondria staining kit (Sigma-Aldrich, Saint 
Louis, MO, USA), which contains the cationic lipophilic 
dye JC-1, was used to detect changes in the MMP in LP-1 
cells after plasma treatment following the manufacturer’s 
instruction. After incubation for 24 h, 1 mL LP-1 cell 
suspension (1×106/mL) was collected from each treatment 
and mixed with 1 mL prepared staining solution with JC-1 
at a final concentration of 2.5 μg/mL. The mixture was 
incubated for 20 min at 37°C in an incubator containing 
5% CO2. After washing with ice-cold 1× JC-1 staining 
buffer, the cells were resuspended in 0.5 mL staining 
buffer. The stained cells were observed by fluorescence 
microscopy (BX53; Olympus, Japan), following the step 
of concentrating the suspensions onto microslides by 
centrifugation for 15 min at 750 rpm with a cytocentrifuge 
(Cytopro; Wescor, Logan, UT, USA), as well as analyzed 
directly by flow cytometry (BD). Valinomycin-treated 
cells were used as positive control, because valinomycin 
can dissipate the MMP in LP-1 cells.
Stability of lysosomal membrane
Lucifer yellow CH (Sigma-Aldrich, 2 mg/ml 
stock solution in PBS), which indicates the stability and 
leakage of lysosomes, wasadded to LP-cells at a final 
concentration of 100 μg/ml and incubated overnight. Then, 
the cells were washed three times with PBS and seeded 
on a 24-well plate. Next, the stained LP-cells were treated 
with plasma for 0 min (control group), 0.5 min, 1 min and 
2 min. After incubation for 24 h, cells were washed twice 
and concentrated onto a glass slide using a cytocentrifuge 
(Cytopro; Wescor, Logan, UT, USA) for observation of the 
cell status via fluorescence microscopy (BX53; Olympus, 
Japan).
Human apoptosis array kit
Human Apoptosis Array Kit (R&D Systems, 
Minneapolis, MN, USA), which can detect 35 different 
proteins like Bad, Bax, BCL-2, Fas and HSP27 etc., 
was purchased for analyzing the expression profiles of 
apoptosis-related proteins induced by plasma treatment 
for 1 min. After 24 h incubation, LP-1 cells treated with or 
without plasma were rinsed with PBS and solubilized in 
lysis buffer 17 for 30 min at 4°C, followed by centrifuging 
at 14,000 rpm for 5 min, then the supernate was transferred 
and protein concentration was quantified. Cell lysates with 
300 μg protein was added and incubated overnight at 4°C 
after blocking membrane with array buffer 1. Following 
washing each array with 1×wash buffer for 10 min twice, 
1.5 mL of detection antibody cocktail was added and 
incubated 1 h on a rocking platform shaker. Then the array 
was washed and 2.0 mL of Streptavidin-HRP was pipetted 
into each well and incubated for 30 min. After washing 
each array, the protein spots were visualized using Chemi 
Reagent Mix by Chemi-Doc-it Imaging System (UVP, 
Upland, CA, USA) and the intensity was determined by 
ImageJ Version 1.45 software.
Analysis of CD95 expression by flow cytometry
The expression of CD95 was assayed by 
immunofluorescence staining using flow cytometry. In brief, 
LP-1 cells were harvested and washed twice with PBS. 
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Then, the cells were incubated with 5 μL of CD95-FITC 
(BioLegend, San Diego, CA, USA) in 50 μL PBS for 30 min 
at room temperature in the dark. After that, the cells were 
washed with PBS and resuspended in 400 μL PBS for flow 
cytometric (C6) analysis. Mouse IgG1-FITC (Biolegend, San 
Diego, CA, USA) was used as an isotype control for CD95 
in this experiment. The MFI (mean fluorescence intensity) 
ratio was determined as follows: MFI ratio = MFI of CD95 
expression / MFI of isotype control.
Transfection with siRNA
Lipofectamine 2000 was used to transfect CD95-
targeting siRNA into LP-1 cells to knock down the 
expression of CD95 following the manufacturer’s 
instructions. Briefly, at the time of transfection, 1×105 
cells/well were plated in 24-well plates with culture 
medium. For each sample, cells were transfected with 
CD95-targeting siRNA (Santa Cruz, CA, USA) at a final 
concentration of 125 nM using 6 μL of Lipofectamine 
2000 reagent (Invitrogen, Carlsbad, CA, USA). A scramble 
siRNA was used as control siRNA. After incubation for 
48 h, cell viability and cell apoptosis were analyzed, and 
CD95 expression was determined by real-time PCR, WB 
and flow cytometry as mentioned. Then, the cells were 
treated with plasma for further experiments.
Detection of ROS
In our experiment, CMH2-DCFDA (Invitrogen, 
Grand Island, NY, USA) was used to detect ROS 
concentration. Cells (1×105) were plated in 24-well plates 
with 300 μL complete medium and treated with plasma for 
0.5 min, 1 min and 2 min with or without 5 mM/10 mM 
NAC. After 24 h, 10 μM of CMH2-DCFDA was incubated 
with the LP-1 cells for 30 min at 37°C. Extracellular ROS 
was measured with a microplate reader (Thermo Scientific) 
with excitation/emission at 485/530 nm using the protocol 
for “Fluorometric” measurement. Then, the cells were 
washed three times with PBS and collected for analysis of 
intracellular ROS using a flow cytometer (Accuri C6).
Enzyme activity of caspase3/8/9
Caspase colorimetric assay kit (Biovision, USA) was 
used to evaluate caspase activity in LP-1 cells treated with 
plasma for 0.5 min, 1 min and 2 min. NAC was added to 
the cells at a final concentration of 10 mM followed by 2 
min plasma treatment. After incubation for 6 h and 9 h, cells 
were resuspended in 50 μL cell lysis buffer and incubated 
on ice for 10 min. Then, the concentration of protein in the 
centrifuged supernatant was assayed. Samples with 150 
μg protein in 50 μL cell lysis buffer were added to 96-well 
plates and cultured with 50 μL of 10 mM DTT and 5 μL of 
4 mM substrate at 37°C for 1.5 h. The absorbance was read 
at 400 nm in a microtiter plate reader (Thermo Scientific).
Western blot
After plasma treatment for 48h, cell protein was 
extracted using RIPA lysis buffer (Sigma), and the 
concentration was determined by BCA protein assay 
kit (Sigma). Protein samples were denatured with 
5×protein loading buffer at 95°C for 5min and separated 
in 12.5% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (Bio-Rad, Hercules, CA, 
USA). Subsequently, proteins were transferred to 0.2 
μm of polyvinylidene difluoride membranes (Millpore, 
Billerica, MA, USA) at 70 V for 2.5 h. After blocking 
with 5% non-fat milk for 2 h at room temperature, the 
membrane was incubated with primary antibody and 
then washed with TBST three times. The horseradish 
peroxidase (HRP)–conjugated secondary antibodies, 
goat anti-rabbit IgG and anti-mouse IgG (1:2000) 
(Abgent, San Diego, CA, USA), were added and 
incubated for 1h on a horizontal orbital shaker. Images 
were visualized with ECL chemiluminescent substrate 
(Millipore, Bedford, MA, USA) using a ChemiDoc-It 
510 system (UVP, Upland, CA, USA) and protein bands 
were analyzed by densitometric analysis using ImageJ 
software. Primary antibody against human included 
caspase-3 (1:500), caspase-8 (1:500), caspase-9 (1:500), 
phospho-p53 (1:200) (Cell Signaling Technology, 
Danvers, MA, USA), CD95 (1:200) (Santa Cruz, CA, 
USA) and β-actin (1:1000) (Immuno Way, Newark, DE, 
USA).
Real-time PCR
To quantify the relative mRNA expression 
of CD95 (Fas), real-time PCR was performed after 
plasma treatment (24 h later) or siRNA trasfection 
(48 h later). Total RNA was extracted from LP-1 cells 
using EZNA total RNA kit II (Omega Bio-Tec Inc., 
Doraville, GA, USA). After quantifying with Nano Drop 
spectrophotometry (BioTek® Instruments Inc., Winooski, 
VT, USA), 2 μg of total RNA was used for the synthesis 
of fist strand cDNA using RevertAid first strand cDNA 
synthesis kit (Thermo Scientific, Waltham, MA, USA), 
which performed on Applied Biosystems Veriti™ Thermal 
Cycler (Applied Biosystems, Foster City, CA, USA). All 
real-time PCR reactions were set up in a 20 μL mixture 
containing 1/2 volume of 2×QuantiFast SYBR Green 
PCR MasterMix (Qiagen, Hilden, NRW, Germany), 
0.5 μM of primer, 1 μL of cDNA templates and 8 μL of 
DNAase-RNase Free water. The above reactions were run 
on Bio-Rad CFX Connect™ Real-time System (Bio-Rad, 
Foster City, CA, USA) and amplified with a optimized 
cycling condition: 5 min at 95°C, then 10 s at 95°C 
and 30 s at 60°C for 38 cycles; the melting curves were 
obtained by slow heating (0.5°C/s) from 60°C to 95°C. 
The primers were designed by Shenggong Company 
(Shanghai, China) and the sequences were showed below: 
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Fas forward, 5′-CCCAGAATACCAAGTGCAG-3′; Fas 
reverse, 5′-GTGCATTCCTTGATGATTCCA-3′; β-actin 
forward, 5′-CATGTACGTTGCTATCCAGGC-3′; β-actin 
reverse, 5′-CTCCTTAATGTCACGCACGAT-3′. The 
relative expression of CD95 was normalized against a 
housekeeping gene of β-actin using the ΔΔCt method.
Effect of p53 inhibitor Pifithrin-α on CD95 
expression and plasma-induced cell apoptosis
LP-1 cells (1×105/well) were seeded in 24-well plates 
with 300 μL RPMI 1640 medium and pretreated with 10 
μM of PFT-α (Target Mol, Boston, MA, USA), which is 
an inhibitor of p53, for 1 h at 37°C prior to treatment for 2 
min with plasma. After incubation for 48 h, apoptosis was 
examined by western blotting as previously described.
ChIP assay
ChIP assay was performed on LP-1 cells with Magna 
ChIP™ A/G (Millipore; Billerica, MA, USA) following 
the manufacturer’s instructions. Cells (1×106) were 
treated with or without (control group) He+O2 plasma for 
1 min; after incubation for 24 h, cells were collected and 
fixed in 1% formaldehyde for cross-linking. The mixture 
was incubated at room temperature for 10 min, and 10× 
Glycine was added to quench the unreacted formaldehyde. 
After incubation for 5 min, the cells were centrifuged 
and washed twice with cold 1× PBS. The cell pellet was 
incubated with 0.5 mL of cell lysis buffer containing 1× 
protease inhibitor cocktail II for 15 min on ice. Then, 
the chromatin was isolated by adding 0.5 mL of nuclear 
lysis buffer containing 1× protease inhibitor cocktail II, 
followed by sonication to obtain sheared DNA. Chromatin 
DNA fragments were diluted in 450 μL of dilution buffer 
containing protease inhibitor cocktail II and precipitated 
with antibodies against phospho-p53 (1:100) (Cell 
Signaling Technology) or isotype control IgG including 20 
μL of fully resuspended protein A/G magnetic beads at 4°C 
overnight with rotation. Protein A/G magnetic beads were 
precipitated with a magnetic separator and washed with low 
salt, high salt, LiCl and TE Wash Buffer in sequence. Next, 
the cross-linked protein/DNA complexes were reversed to 
free DNA by incubating at 62°C for 2 h with shaking in 
the presence of 100 μL of ChIP elution buffer and 1 μL 
of proteinase K followed by incubation at 95°C for 10 
min. Then, DNA was purified and used as a template for 
PCR and real-time PCR using the following primer pairs: 
5’-GGATAATTAGACGTACGTGGGC-3’ (forward) and 
5’-GGACAATTGACAAAATCAGTATC-3’ (reverse) [63]. 
The PCR products were detected on a 2% agarose gel.
Preparation and analysis of MM clinical samples
Seven newly diagnosed MM patients were chosen 
from the Department of Hematology, Xijing Hospital of 
Xi’an. The basic information on these patients is listed in 
Supplementary Table 1, including gender, age and blood 
test results. Bone marrow samples were also obtained and 
tested using Giemsa staining to measure the percentage 
of MM tumor cells. MM tumor cells were sorted using 
MACS (magnetic-activated cell sorting) from the bone 
marrow samples. Briefly, 20 mL bone marrow (with 
heparin) was centrifuged and washed with PBS and 
resuspended in 7 mL of Ficoll (lymphocyte separation 
medium). The cells were centrifuged at 1800 rpm for 20 
min, and the middle layer was isolated for staining with 
CD138-conjugated magnetic beads. After incubation 
at 4°C for 15 min, the cells were washed with PBS and 
sorted with MACS columns. The positively selected cells 
were considered MM tumor cells, and the rest of the 
cells mostly were bone marrow stromal cells that were 
considered as the control group. The sensitivity treatment 
of these cells to plasma was detected by a cell viability 
assay, and CD95 expression was measured by flow 
cytometry and western blotting.
Genetic alterations in MM patients detected by 
FISH
To evaluate the prognosis of MM patients, a FISH 
kit was used to detect gene abnormalities in MM. The 
kit can detect several common genetic abnormalities 
in MM, including RB1 deletion, 13q14 deletion, 1q21 
amplification and 14q32 translocation (Supplementary 
Table 2). FISH was performed according to the 
manufacturer’s instructions; the results were analyzed 
using the ratio of the number of positive cells to the total 
number of cells (counting for more than 200).
Statistical analysis
All samples were prepared in triplicate, and 
experiments were repeated at least three times. The data 
are presented as the means ± SD. Differences between 
groups were evaluated using one-way ANOVA and 
Student’s T test. P < 0.05 was considered statistically 
significant.
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